Kenneth J. Fraunhoffer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kenneth J. Fraunhoffer has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Alan Steven
Process Chemist
3 shared publications - Jack A. Terrett
Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
3 shared publications Jingjun Yin
Merck and Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
3 shared publications- John Hayler
Chemical Development, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom
3 shared publications - Lucie E. Lovelle
NovartisPharma AG, Forum 1, Novartis Campus, 4056 Basel, Switzerland
3 shared publications Marie-Gabrielle Braun
Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
3 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
The Synthetic Role of PFAS in Drug Substance Manufacturing: An IQ Consortium Working Group Review on the Potential Impact of PFAS Restrictions on Patient Access to Medicines
Per- and polyfluoroalkyl substances (PFAS) have been widely used in consumer and industrial applications including the pharmaceutical industry. This widespread adoption throughout society has recently come under scrutiny due to human health and environmental concerns associated with the toxicity and environmental persistence of certain PFAS. Within the IQ Consortium, a Working Group (WG) focusing on drug substance manufacturing has been established to assess the prevalence of PFAS in commercial drug substance manufacturing and the potential impact of PFAS regulations on patient access to medicines. To address gaps in current definitions, we introduce a functional classification─visible, contributing, and invisible PFAS─to distinguish PFAS present in marketed active pharmaceutical ingredients (APIs), those essential for installing PFAS moieties into APIs, and reagents or solvents enabling synthesis without remaining in the final product. Survey data from IQ Consortium member companies and literature analysis confirm extensive PFAS use and presence across the drug substance supply chain. These findings highlight that broad PFAS restrictions could disrupt manufacturing, necessitate significant process redevelopment and regulatory revalidation, and jeopardize continuity of supply. Proactive engagement and risk mitigation strategies are critical to balance environmental objectives with uninterrupted patient access to essential medicines.
- 29 July 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
Open AccessThe Synthetic Role of PFAS in Drug Substance Manufacturing: An IQ Consortium Working Group Review on the Potential Impact of PFAS Restrictions on Patient Access to Medicines
Per- and polyfluoroalkyl substances (PFAS) have been widely used in consumer and industrial applications including the pharmaceutical industry. This widespread adoption throughout society has recently come under scrutiny due to human health and environmental concerns associated with the toxicity and environmental persistence of certain PFAS. Within the IQ Consortium, a Working Group (WG) focusing on drug substance manufacturing has been established to assess the prevalence of PFAS in commercial drug substance manufacturing and the potential impact of PFAS regulations on patient access to medicines. To address gaps in current definitions, we introduce a functional classification─visible, contributing, and invisible PFAS─to distinguish PFAS present in marketed active pharmaceutical ingredients (APIs), those essential for installing PFAS moieties into APIs, and reagents or solvents enabling synthesis without remaining in the final product. Survey data from IQ Consortium member companies and literature analysis confirm extensive PFAS use and presence across the drug substance supply chain. These findings highlight that broad PFAS restrictions could disrupt manufacturing, necessitate significant process redevelopment and regulatory revalidation, and jeopardize continuity of supply. Proactive engagement and risk mitigation strategies are critical to balance environmental objectives with uninterrupted patient access to essential medicines.
- 2 August 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (32) , 8974-8978
One-Pot Three-Component Reaction for the Synthesis of 3-Sulfonyl-2-aminopyridines
A general protocol was developed for the synthesis of 3-sulfonyl-2-aminopyridines, valuable building blocks in drug development. The three-component one-pot coupling between various N,N-dimethylacroleines, sulfonylacetonitriles, and primary amines/ammonia yields the desired products that are isolated with high purity and excellent yields without the need of column chromatography. The scope of the reaction demonstrates remarkable versatility and scalability, making it highly suitable for large-scale applications in process and medicinal chemistry.
- 2 August 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (32) , 8974-8978
One-Pot Three-Component Reaction for the Synthesis of 3-Sulfonyl-2-aminopyridines
A general protocol was developed for the synthesis of 3-sulfonyl-2-aminopyridines, valuable building blocks in drug development. The three-component one-pot coupling between various N,N-dimethylacroleines, sulfonylacetonitriles, and primary amines/ammonia yields the desired products that are isolated with high purity and excellent yields without the need of column chromatography. The scope of the reaction demonstrates remarkable versatility and scalability, making it highly suitable for large-scale applications in process and medicinal chemistry.
- 3 June 2022
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 41 (14) , 1847-1864
Advancing Base Metal Catalysis through Data Science: Insight and Predictive Models for Ni-Catalyzed Borylation through Supervised Machine Learning
- 3 June 2022
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 41 (14) , 1847-1864
Advancing Base Metal Catalysis through Data Science: Insight and Predictive Models for Ni-Catalyzed Borylation through Supervised Machine Learning
- 16 August 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (43) , 23182-23186
Sustainable Pd(OAc)2/Hydroquinone Cocatalyst System for Cis‐Selective Dibenzoyloxylation of 1,3‐Cyclohexadiene
The 1,4‐diacyloxylation of 1,3‐cyclohexadiene (CHD) affords valuable stereochemically defined scaffolds for natural product and pharmaceutical synthesis. Existing cis‐selective diacyloxylation protocols require superstoichiometric quantities of benzoquinone (BQ) or MnO2, which limit process sustainability and large‐scale application. In this report, reaction development and mechanistic studies are described that overcome these limitations by pairing catalytic BQ with tert‐butyl hydroperoxide as the stoichiometric oxidant. Catalytic quantities of bromide enable a switch from trans to cis diastereoselectivity. A catalyst with a 1:2 Pd:Br ratio supports high cis selectivity while retaining good rate and product yield. Further studies enable replacement of BQ with hydroquinone (HQ) as a source of cocatalyst, avoiding the handling of volatile and toxic BQ in large‐scale applications.
- 16 August 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (43) , 23182-23186
Sustainable Pd(OAc)2/Hydroquinone Cocatalyst System for Cis‐Selective Dibenzoyloxylation of 1,3‐Cyclohexadiene
The 1,4‐diacyloxylation of 1,3‐cyclohexadiene (CHD) affords valuable stereochemically defined scaffolds for natural product and pharmaceutical synthesis. Existing cis‐selective diacyloxylation protocols require superstoichiometric quantities of benzoquinone (BQ) or MnO2, which limit process sustainability and large‐scale application. In this report, reaction development and mechanistic studies are described that overcome these limitations by pairing catalytic BQ with tert‐butyl hydroperoxide as the stoichiometric oxidant. Catalytic quantities of bromide enable a switch from trans to cis diastereoselectivity. A catalyst with a 1:2 Pd:Br ratio supports high cis selectivity while retaining good rate and product yield. Further studies enable replacement of BQ with hydroquinone (HQ) as a source of cocatalyst, avoiding the handling of volatile and toxic BQ in large‐scale applications.
- 16 August 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (43) , 23366-23370
Sustainable Pd(OAc)2/Hydroquinone Cocatalyst System for Cis‐Selective Dibenzoyloxylation of 1,3‐Cyclohexadiene
The 1,4‐diacyloxylation of 1,3‐cyclohexadiene (CHD) affords valuable stereochemically defined scaffolds for natural product and pharmaceutical synthesis. Existing cis‐selective diacyloxylation protocols require superstoichiometric quantities of benzoquinone (BQ) or MnO2, which limit process sustainability and large‐scale application. In this report, reaction development and mechanistic studies are described that overcome these limitations by pairing catalytic BQ with tert‐butyl hydroperoxide as the stoichiometric oxidant. Catalytic quantities of bromide enable a switch from trans to cis diastereoselectivity. A catalyst with a 1:2 Pd:Br ratio supports high cis selectivity while retaining good rate and product yield. Further studies enable replacement of BQ with hydroquinone (HQ) as a source of cocatalyst, avoiding the handling of volatile and toxic BQ in large‐scale applications.
- 16 August 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (43) , 23366-23370
Sustainable Pd(OAc)2/Hydroquinone Cocatalyst System for Cis‐Selective Dibenzoyloxylation of 1,3‐Cyclohexadiene
The 1,4‐diacyloxylation of 1,3‐cyclohexadiene (CHD) affords valuable stereochemically defined scaffolds for natural product and pharmaceutical synthesis. Existing cis‐selective diacyloxylation protocols require superstoichiometric quantities of benzoquinone (BQ) or MnO2, which limit process sustainability and large‐scale application. In this report, reaction development and mechanistic studies are described that overcome these limitations by pairing catalytic BQ with tert‐butyl hydroperoxide as the stoichiometric oxidant. Catalytic quantities of bromide enable a switch from trans to cis diastereoselectivity. A catalyst with a 1:2 Pd:Br ratio supports high cis selectivity while retaining good rate and product yield. Further studies enable replacement of BQ with hydroquinone (HQ) as a source of cocatalyst, avoiding the handling of volatile and toxic BQ in large‐scale applications.
- 16 April 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (6) , 897-908
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- 16 April 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (6) , 897-908
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- 2 March 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (3) , 334-346
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- 2 March 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (3) , 334-346
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- Open Access
- 11 January 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (2) , 172-182
Safe Scale-up of an Oxygen-Releasing Cleavage of Evans Oxazolidinone with Hydrogen Peroxide
In the pharmaceutical industry, H2O2-mediated oxidation reactions are commonly used in chemical syntheses but they can also introduce unexpected safety hazards. Our labs recently reported on the discovery of oxygen evolution during the LiOH/H2O2-mediated cleavage of Evans oxazolidinone. Faced with this previously unexpected hazard, the authors, herein, report on the development and demonstration of a methodology for the safe scale-up of this O2-releasing reaction. It was found that O2 in the headspace could be controlled by a combination of N2 sweeping and modulation of the LiOH addition rate. A design of experiment study was used to probe the multivariate parameter space in order to minimize formation of the unstable peracid intermediate, thus avoiding accumulation and subsequent risk of rapid and uncontrolled O2 release. To support scale-up, the well-mixed vapor headspace assumption was tested using computational fluid dynamics, and it was found that N2 sparging is effective at reducing heterogeneity in the headspace. Condenser conditions were evaluated to balance recovery of solvent—because of the high N2 sweep—and avoid the risk of condenser freezing—because of the presence of water in the condensate. An additional fail safe was developed, using a pH buffer to rapidly halt the base-catalyzed reaction in the case of an unexpectedly high headspace O2 concentration. The final process was validated and executed at up to 215 kg scale.
- 11 January 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (2) , 172-182
Open AccessSafe Scale-up of an Oxygen-Releasing Cleavage of Evans Oxazolidinone with Hydrogen Peroxide
In the pharmaceutical industry, H2O2-mediated oxidation reactions are commonly used in chemical syntheses but they can also introduce unexpected safety hazards. Our labs recently reported on the discovery of oxygen evolution during the LiOH/H2O2-mediated cleavage of Evans oxazolidinone. Faced with this previously unexpected hazard, the authors, herein, report on the development and demonstration of a methodology for the safe scale-up of this O2-releasing reaction. It was found that O2 in the headspace could be controlled by a combination of N2 sweeping and modulation of the LiOH addition rate. A design of experiment study was used to probe the multivariate parameter space in order to minimize formation of the unstable peracid intermediate, thus avoiding accumulation and subsequent risk of rapid and uncontrolled O2 release. To support scale-up, the well-mixed vapor headspace assumption was tested using computational fluid dynamics, and it was found that N2 sparging is effective at reducing heterogeneity in the headspace. Condenser conditions were evaluated to balance recovery of solvent—because of the high N2 sweep—and avoid the risk of condenser freezing—because of the presence of water in the condensate. An additional fail safe was developed, using a pH buffer to rapidly halt the base-catalyzed reaction in the case of an unexpectedly high headspace O2 concentration. The final process was validated and executed at up to 215 kg scale.
- 6 November 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (11) , 2287-2301
Green Chemistry Articles of Interest to the Pharmaceutical Industry
- 6 November 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (11) , 2287-2301
Green Chemistry Articles of Interest to the Pharmaceutical Industry